Abbott Laboratories (ABT) Long-Term Debt Repayments (2010 - 2026)

Abbott Laboratories has disclosed Long-Term Debt Repayments across 15 years of filings, most recently posting $1.4 billion for Q2 2026.

• In Q2 2026, Long-Term Debt Repayments rose 140400.0% year-over-year to $1.4 billion; the TTM figure through Jun 2026 stood at $3.3 billion (up 225.15% YoY), while the FY2021 annual figure was $48.0 million, down 96.4% from the prior year.
• Long-Term Debt Repayments came in at $1.4 billion for Q2 2026 at Abbott Laboratories, down from $1.4 billion in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of $1.4 billion in Q3 2023 to a low of $1.0 million in Q2 2022.
• Average Long-Term Debt Repayments over 5 years is $545.3 million, with a median of $259.5 million recorded in 2024.
• Year-over-year, Long-Term Debt Repayments surged 144400.0% in 2023 and plunged 99.86% in 2024.
• Over 5 years, Long-Term Debt Repayments stood at $1.0 million in 2022, then surged by 144400.0% to $1.4 billion in 2023, then sank by 99.86% to $2.0 million in 2024, then jumped by 24950.0% to $501.0 million in 2025, then soared by 180.44% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Debt Repayments figures were $1.4 billion in Q2 2026, $1.4 billion in Q1 2026, and $501.0 million in Q3 2025.